Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Br J Cancer ; 112(4): 630-5, 2015 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-25584488

RESUMEN

PURPOSE: To study the impact of adjuvant trastuzumab among patients achieving a pathologic complete response (pCR) after trastuzumab-based neoadjuvant systemic therapy (NST). PATIENTS AND METHODS: Patients with primary HER2-positive breast cancer treated with trastuzumab-based NST were categorised according to adjuvant trastuzumab administration and pCR status. Adjuvant trastuzumab became standard of care in 2006, this was the main reason patients in our cohort did not receive adjuvant trastuzumab. Kaplan-Meier was used to estimate survival. A test for interaction between adjuvant trastuzumab and pCR was completed. FINDINGS: Of 589 patients, 203 (34.5%) achieved a pCR. After surgery, 109 (18.5%) patients in the entire cohort did not receive adjuvant trastuzumab. Among patients achieving a pCR, 31.3% received adjuvant trastuzumab compared with 68.8% among those who did not achieve a pCR (P=0.0006). Among patients achieving pCR, adjuvant trastuzumab did not further improve overall survival (OS) or relapse-free survival (RFS) (P=0.35 and P=0.93, respectively). Any benefit of adjuvant trastuzumab in OS and RFS among patients without a pCR did not achieve statistical significance (P=0.3 and P=0.44, respectively). CONCLUSIONS: In this cohort, patients treated with trastuzumab-based NST who achieved a pCR have excellent outcome regardless of whether they received adjuvant trastuzumab.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Carcinoma Ductal de Mama/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/administración & dosificación , Receptor ErbB-2/antagonistas & inhibidores , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/genética , Neoplasias de la Mama/mortalidad , Carcinoma Ductal de Mama/genética , Carcinoma Ductal de Mama/mortalidad , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Epirrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Terapia Neoadyuvante , Paclitaxel/administración & dosificación , Receptor ErbB-2/genética , Estudios Retrospectivos , Trastuzumab
2.
Br J Pharmacol ; 164(7): 1899-915, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21557739

RESUMEN

BACKGROUND AND PURPOSE: The lack of safe and effective treatments for obesity has increased interest in natural products that may serve as alternative therapies. From this perspective, we have analysed the effects of daidzein, one of the main soy isoflavones, on diet-induced obesity in rats. EXPERIMENTAL APPROACH: Rats made obese after exposure to a very (60%) high fat-content diet were treated with daidzein (50 mg·kg(-1)) for 14 days. The dose was selected on the basis of the acute effects of this isoflavone on a feeding test. After 14 days, animals were killed and plasma, white and brown adipose tissue, muscle and liver studied for the levels and expression of metabolites, proteins and genes relevant to lipid metabolism. KEY RESULTS: A single treatment (acute) with daidzein dose-dependently reduced food intake. Chronic treatment (daily for 14 days) reduced weight gain and fat content in liver, accompanied by high leptin and low adiponectin levels in plasma. While skeletal muscle was weakly affected by treatment, both adipose tissue and liver displayed marked changes after treatment with daidzein, affecting transcription factors and lipogenic enzymes, particularly stearoyl coenzyme A desaturase 1, a pivotal enzyme in obesity. Expression of uncoupling protein 1, an important enzyme for thermogenesis, was increased in brown adipose tissue after daidzein treatment. CONCLUSIONS AND IMPLICATIONS: These results support the use of isoflavones in diet-induced obesity, especially when hepatic steatosis is present and open a new field of use for these natural products.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Dieta Alta en Grasa , Hígado Graso/tratamiento farmacológico , Isoflavonas/uso terapéutico , Obesidad/tratamiento farmacológico , Estearoil-CoA Desaturasa/metabolismo , Acetil-CoA Carboxilasa/metabolismo , Acil-CoA Oxidasa/metabolismo , Adiponectina/sangre , Tejido Adiposo/efectos de los fármacos , Tejido Adiposo/metabolismo , Tejido Adiposo Blanco/efectos de los fármacos , Tejido Adiposo Blanco/metabolismo , Animales , Fármacos Antiobesidad/farmacología , Peso Corporal/efectos de los fármacos , Modelos Animales de Enfermedad , Ingestión de Alimentos/efectos de los fármacos , Ácido Graso Sintasas/metabolismo , Hígado Graso/metabolismo , Insulina/sangre , Isoflavonas/farmacología , Leptina/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Obesidad/metabolismo , PPAR alfa/metabolismo , PPAR gamma/metabolismo , Ratas , Ratas Wistar
3.
Eur J Clin Nutr ; 65(3): 321-8, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21179052

RESUMEN

BACKGROUND: Vitamin D deficiency is common worldwide. No homogenous reference values have yet been established and no studies of values have been conducted in Spain involving a large number of participants. OBJECTIVE: To study the population concentrations of vitamin D in a representative sample of the Spanish population. SUBJECTS/METHODS: The study involved two cohorts from Spain, the Asturias study and the Pizarra study, which are two prospective, population-based studies involving 2260 participants. In 1262 subjects (age: 20-83 years) we studied 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), calcium, phosphorus and creatinine. RESULTS: The median population values of 25-hydroxyvitamin D and iPTH were 22.46 ng/ml and 42.29 pg/ml, respectively. The values of 25-hydroxyvitamin D were significantly higher in summer and correlated with age (ß = -0.05 ± 0.01, P < 0.0001), creatinine (ß = 6.42 ± 1.17, P < 0.0001) and iPTH (-0.07 ± 0.01, P < 0.0001), but not with calcium, phosphorus or sex. The increase in iPTH with age was seen whatever the values of 25-hydroxyvitamin D, and was greater in the older persons. The concentration of iPTH rose continuously with effect from 25-hydroxyvitamin D values below ≈30 ng/ml. Values above ≈35 ng/ml were associated with a significantly lower concentration of iPTH. CONCLUSIONS: One-third (33.9%) of the Spanish population may be at risk for Vitamin D deficiency. The 25-hydroxyvitamin D values above 30 ng/ml can safely discard 'hyper PTH'. The increase in iPTH concentration is greater in older persons for similar values of 25-hydroxyvitamin D.


Asunto(s)
Deficiencia de Vitamina D/epidemiología , Vitamina D/análogos & derivados , Adulto , Anciano , Anciano de 80 o más Años , Calcio/sangre , Estudios de Cohortes , Creatinina/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Fósforo/sangre , Prevalencia , Valores de Referencia , Factores de Riesgo , Estaciones del Año , España/epidemiología , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Adulto Joven
4.
Mol Cell Biochem ; 293(1-2): 79-85, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16933031

RESUMEN

The essential amino acid tryptophan is the precursor in the anabolic pathway of melatonin, a hormone with immunomodulatory properties. The present study shows the in vivo effect of tryptophan on the phagocytic function and oxidative metabolism of heterophils from Streptopelia roseogrisea of < 1 year of age, with a parallel evaluation of the plasma levels of melatonin. The L-tryptophan was administered orally (125 and 300 mg/kg b.w.) at 19:00, before the beginning of the period of darkness, for 7 days. At the end of the tryptophan treatment, determinations were made at 21:00 and 02:00 of the Phagocytosis Index, the Phagocytosis Percentage, the Phagocytic Efficiency and the superoxide anion levels in heterophils isolated from blood and of the plasma levels of melatonin. The results showed, for the determinations at 21:00 in the animals that had received 125 mg L-tryptophan/kg b.w., enhanced heterophil phagocytic function and raised levels of plasma melatonin, with no affect on the oxidative metabolism of the phagocytes. For the administration of the greater concentration of tryptophan (300 mg/kg b.w.), there were raised plasma melatonin levels together with increases in heterophil phagocytic capacity and phagocyte oxidative metabolism at 02:00. The results indicate that tryptophan administered orally at night to diurnal animals of less than 1 year in age affects the circulating levels of melatonin at the same time as inducing stimulation of the innate immune function.


Asunto(s)
Leucocitos/inmunología , Melatonina/sangre , Fagocitosis/efectos de los fármacos , Triptófano/farmacología , Administración Oral , Animales , Cronoterapia , Columbidae/clasificación , Columbidae/metabolismo , Interpretación Estadística de Datos , Depuradores de Radicales Libres/administración & dosificación , Depuradores de Radicales Libres/farmacología , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Estrés Oxidativo/efectos de los fármacos , Superóxidos/metabolismo , Triptófano/administración & dosificación
5.
J Clin Oncol ; 22(12): 2284-93, 2004 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-15136595

RESUMEN

PURPOSE: The goal of this study was to examine the feasibility of developing a multigene predictor of pathologic complete response (pCR) to sequential weekly paclitaxel and fluorouracil + doxorubicin + cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer. PATIENTS AND METHODS: All patients underwent one-time pretreatment fine-needle aspiration to obtain RNA from the cancer for transcriptional profiling using cDNA arrays containing 30721 human sequence clones. Analysis was performed after profiling, and 42 patients' clinical results were available, 24 of which were used for predictive marker discovery; 18 patients' results were used as an independent validation set. RESULTS: Thirty-one percent of patients had pCR (six discovery and seven validation), defined as disappearance of all invasive cancer in the breast after completion of chemotherapy. We could identify no single marker that was sufficiently associated with pCR to be used as an individual predictor. A multigene model with 74 markers (P

Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Fluorouracilo/uso terapéutico , Perfilación de la Expresión Génica , Paclitaxel/administración & dosificación , Adulto , Anciano , Quimioterapia Adyuvante , Estudios de Factibilidad , Humanos , Persona de Mediana Edad , Terapia Neoadyuvante , Pronóstico , Resultado del Tratamiento
6.
Sci Total Environ ; 291(1-3): 135-41, 2002 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-12150433

RESUMEN

Serum concentrations were measured in individuals (n = 50) with liver diseases (cirrhosis and hepatitis) by hydride generation atomic absorption spectrometry in a cross-sectional study. Mean serum selenium levels determined in patients with cirrhosis (n = 12) or with hepatitis (n = 38) were significantly lower (P<0.01) than those measured in control groups mainly due to a decreased liver function. Mean serum selenium concentrations were significantly lower in cirrhotic individuals when compared with patients with hepatitis (P<0.05). Therefore, the severity of the live injury is a factor conditioning the impairment in the selenium body status observed in individuals with hepatopathies. In hepatic patients serum total cholesterol levels showed a significant correlation with serum selenium concentrations (r=0.912, P<0.05) demonstrating the important role of selenium as an antioxidant agent; similarly, gamma-glutamic-transferase levels were significantly correlated with the serum selenium levels (r=-0.803, P<0.05) indicating that when the intensity of the hepatic injury increases (enhancement in serum GGT levels) concomitantly the serum selenium levels decrease significantly. No significant relationships between serum selenium levels and sex or age of patients were observed.


Asunto(s)
Hepatitis/sangre , Cirrosis Hepática/sangre , Selenio/sangre , Adulto , Anciano , Colesterol/sangre , Estudios Transversales , Femenino , Hepatitis/patología , Humanos , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Espectrofotometría Atómica , gamma-Glutamiltransferasa/sangre
7.
Cancer ; 92(7): 1775-82, 2001 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-11745249

RESUMEN

BACKGROUND: Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Anthracycline-based regimens represent the standard of treatment for IBC. Reports of significant clinical activity of paclitaxel in metastatic breast carcinoma led the authors to investigate the role of this drug in the management of IBC. METHODS: Forty-four patients with IBC were enrolled between February 1994 and January 1998. The treatment plan consisted of induction chemotherapy (IC), mastectomy, adjuvant chemotherapy, and radiotherapy. Forty-two patients received IC with four cycles of fluorouracil, doxorubicin, and cyclophosphamide. If the clinical response was less than partial, patients were "crossed over" to paclitaxel before mastectomy. All patients received adjuvant paclitaxel. Patients unresectable after paclitaxel were offered high-dose chemotherapy with autologous peripheral blood progenitor cell support. RESULTS: Thirty-four patients (81%) achieved an objective clinical remission; 3 patients (7%) achieved a clinical complete remission, 31 (74%) a partial remission. Six patients (14%) achieved pathologic complete remission. Sixteen patients were treated with paclitaxel, 7 of them (44%) were able to undergo mastectomy. Median time to progression (TTP) was 22 months. Median overall survival (OS) was 46 months. Concordance between clinical and pathologic response was documented in only 8 patients (24%). No differences in TTP and OS compared with a historical group of 178 IBC patients treated with anthracycline-based regimens. CONCLUSIONS: Paclitaxel improves tumor resectability in anthracycline-refractory IBC. The impact of paclitaxel on the prognosis of IBC needs to be better evaluated in future trials using more dose-intensive schedules of administration. New imaging modalities may contribute to improve assessment of response to IC.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Paclitaxel/uso terapéutico , Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Mastectomía , Persona de Mediana Edad , Inducción de Remisión , Análisis de Supervivencia
8.
Am J Surg ; 182(6): 601-8, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11839324

RESUMEN

BACKGROUND: This study was performed to investigate the extent of tumor downstaging achieved in women with operable breast cancer treated with neoadjuvant chemotherapy and breast-conservation surgery, develop recommendations for effective surgical planning, and report local-regional recurrence rates with this approach. METHODS: One hundred nine patients with stage II or III (T3N1) breast cancer were treated in three prospective trials utilizing four cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC, n = 72) or paclitaxel (n = 37) followed by segmental resection (n = 109) and axillary node dissection (n = 94). Postoperatively, patients received 4 additional cycles of FAC followed by irradiation of the breast. The median follow-up was 53 months. RESULTS: The median tumor size was 4 cm (range 1.1 to 9 cm) at presentation and only 1 cm (range 0 to 4.5 cm) after four cycles of chemotherapy. The primary tumor could not be palpated after chemotherapy in 55% of 104 patients presenting with a palpable mass and therefore required needle localization or ultrasound guidance for surgical resection. Of the 34 patients clinically deemed to have no residual carcinoma in the breast after chemotherapy and before surgery, only 50% of these patients were found to have no residual carcinoma on pathologic examination after surgery. Patients with primary tumors < or =2 cm were significantly more likely than patients with larger tumors to have complete eradication of the primary tumor prior to surgery (P <0.001). The 5-year local-regional recurrence rate was 5%. CONCLUSIONS: Tumor downstaging is marked in patients with operable breast cancer and requires close monitoring during chemotherapy. We recommend placement of metallic tumor markers when the primary tumor is < or =2 cm to facilitate adequate resection and pathologic processing. Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence.


Asunto(s)
Neoplasias de la Mama/terapia , Quimioterapia Adyuvante , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/cirugía , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Paclitaxel/administración & dosificación , Planificación de Atención al Paciente , Estudios Prospectivos , Ultrasonografía
9.
J Natl Cancer Inst ; 92(3): 225-33, 2000 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-10655439

RESUMEN

BACKGROUND: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. PATIENTS AND METHODS: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. RESULTS: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty-nine patients were randomly assigned to FAC and 39 to FAC followed by high-dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P =.35), and 3-year survival rates were 77% and 58%, respectively (P =.23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. CONCLUSIONS: No relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Trasplante de Células Madre Hematopoyéticas , Adulto , Anciano , Neoplasias de la Mama/patología , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Supervivencia sin Enfermedad , Doxorrubicina/administración & dosificación , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Metástasis Linfática , Persona de Mediana Edad , Terapia Neoadyuvante , Estudios Prospectivos , Radioterapia Adyuvante , Análisis de Supervivencia , Trasplante Autólogo , Resultado del Tratamiento
10.
J Clin Oncol ; 17(11): 3412-7, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10550135

RESUMEN

PURPOSE: To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. PATIENTS AND METHODS: Patients with T1-3N0-1M0 disease were randomized to receive either paclitaxel (250 mg/m(2)) as 24-hour infusion or FAC in standard doses at every-3-week intervals. Each patient was treated with four cycles of preoperative chemotherapy. Clinical response and extent of residual disease in the breast and lymph nodes was assessed after four cycles of induction chemotherapy. RESULTS: A total of 174 patients were registered, and 87 were randomized to each arm of the study. Clinical response, ie, complete and partial responses, was similar in both arms of the study. Three patients in the FAC arm and one patient in the paclitaxel subgroup had progressive disease. The extent of residual disease by intent-to-treat analysis at the time of surgery was similar between the two arms of the study. CONCLUSION: The results of this prospective study demonstrated that single-agent paclitaxel as neoadjuvant therapy has significant antitumor activity, and this was clinically comparable to FAC. Similar fractions of patients had clinical complete and partial responses, and very few patients had no response to either therapy. The value of alternate non-cross-resistant therapies as used in this protocol on the clinical course of this disease would require longer follow-up.


Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Paclitaxel/uso terapéutico , Adulto , Anciano , Antineoplásicos Fitogénicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/patología , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Neutropenia/inducido químicamente , Paclitaxel/administración & dosificación , Paclitaxel/efectos adversos , Estudios Prospectivos
11.
Ann Nutr Metab ; 43(1): 30-6, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10364628

RESUMEN

Serum and urine selenium levels were determined in patients with cardiovascular diseases by hydride generation atomic absorption spectrometry. Mean serum Se concentrations measured in patients with acute myocardial infarction (AMI; n = 32) or with ischemic cardiomyopathy (n = 50) were significantly lower than those determined in control groups. In AMI patients, serum triglyceride levels showed a positive significant correlation with the serum Se concentration (r = 0.59, p < 0.05). This result reinforces the important role of Se as an antioxidant agent in this disease. Mean urine Se concentrations of AMI patients (n = 33) were also significantly lower to those determined in the control group (p < 0. 05). This reaction of the organism contributes to regulate the Se homeostasis to keep the body Se status as high as possible.


Asunto(s)
Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/orina , Estado Nutricional , Selenio/sangre , Selenio/orina , Adulto , Anciano , Anciano de 80 o más Años , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/orina , Isquemia Miocárdica/sangre , Isquemia Miocárdica/orina , Encuestas Nutricionales , Factores Sexuales , Triglicéridos/sangre
12.
Sci Total Environ ; 228(1): 79-85, 1999 Mar 22.
Artículo en Inglés | MEDLINE | ID: mdl-10343415

RESUMEN

Serum and urine selenium levels were determined in patients with diabetes by hydride generation atomic absorption spectrometry. Mean serum selenium concentrations measured in patients with diabetes mellitus (64.9 +/- 22.8 micrograms/l) were significantly lower than those determined in the control group (74.9 +/- 27.3 micrograms/l) (P < 0.05). Mean serum selenium concentrations were not significantly different between the two groups of diabetic patients considered (P > 0.05). Mean urine selenium concentration in diabetic patients (18.8 +/- 10.7 micrograms/l) were not significantly different from those measured in the control group (20.2 +/- 10.1 micrograms/l) (P < 0.05). No significant differences in serum and urine selenium levels were found if related to sex of patients (P > 0.05). Application of linear regression analysis to serum and urine selenium levels and patients' age showed a non-statistically significant correlation (P > 0.05). Given the marked overlap between the two ranges of the populations, the predictive values of serum selenium in diabetic patients are low.


Asunto(s)
Diabetes Mellitus/sangre , Diabetes Mellitus/orina , Selenio/sangre , Selenio/orina , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Niño , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/orina , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/orina , Femenino , Homeostasis , Humanos , Masculino , Persona de Mediana Edad
13.
Sci Total Environ ; 212(2-3): 195-202, 1998 Apr 08.
Artículo en Inglés | MEDLINE | ID: mdl-9573630

RESUMEN

A cross-sectional study of serum selenium levels in patients (n = 59) with different types of cancer from southeastern Spain was carried out using hydride generation atomic absorption spectrometry. The subjects were divided into four groups according to the cancer location (respiratory, digestive, haematological and gynaecological groups). Serum selenium levels in all patients (54.41 +/- 24.80 mg/l) were significantly lower (P < 0.001) than those determined in control groups [healthy subjects from the same area (n = 130) and institutionalized elderly people (n = 93)]. Mean serum selenium concentrations were not significantly different among the four groups considered (P > 0.05). Linear regression analyses performed on serum selenium levels and biochemical markers (total cholesterol, triglycerides, transaminases, uric acid and urea) did not establish any statistically significant correlation (P > 0.05). No significant relationships between serum selenium concentrations and sex or age of patients was observed (P > 0.05). Given the marked overlap between the two ranges of the populations (the means are within approx. 1/2 S.D.) the predictive values of serum selenium are low. Thus, there is indeed a statistical significance between the means, but selenium cannot be used to determine whether or not a patient has cancer disease.


Asunto(s)
Neoplasias/sangre , Selenio/sangre , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/sangre , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Biomarcadores de Tumor/sangre , Estudios de Casos y Controles , Colesterol/sangre , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/prevención & control , Estado Nutricional , Selenio/administración & dosificación , Selenio/deficiencia , Triglicéridos/sangre , Urea/sangre , Ácido Úrico/sangre
14.
J Am Acad Dermatol ; 35(1): 74-8, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8682968

RESUMEN

BACKGROUND: Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata. OBJECTIVE: Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss. METHODS: Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial. RESULTS: There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group. CONCLUSION: Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.


Asunto(s)
Alopecia/inducido químicamente , Alopecia/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Minoxidil/uso terapéutico , Administración Cutánea , Adulto , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/efectos adversos , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/efectos adversos , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/efectos adversos , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Método Doble Ciego , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Cabello/efectos de los fármacos , Cabello/crecimiento & desarrollo , Humanos , Persona de Mediana Edad , Minoxidil/administración & dosificación , Proyectos Piloto , Placebos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA